CIK 0001662774 · Non-accelerated filer<br>Smaller reporting company
IRulya Therapeutics Inc.
Sign in to watch- Ticker
- IRLA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 901024039
- Phone
- 203-208-8994
- Business address
- 101 COLLEGE STREET, SUITE 210, NEW HAVEN, CT, 06510
- Former names
- Quince Therapeutics, Inc., Cortexyme, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 70 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-05 | Lamond David Director | Grant or award · Employee Stock Option (right to buy) | +27,000 | 27,000 | ||
| 2024-06-05 | McLoughlin Margaret Director | Grant or award · Employee Stock Option (right to buy) | +27,000 | 27,000 | ||
| 2024-06-05 | RYAN UNA S Director | Grant or award · Employee Stock Option (right to buy) | +27,000 | 27,000 | ||
| 2024-06-05 | Senner Christopher J. Director | Grant or award · Employee Stock Option (right to buy) | +27,000 | 27,000 | ||
| 2024-06-05 | Bray June Director | Grant or award · Employee Stock Option (right to buy) | +27,000 | 27,000 | ||
| 2024-06-05 | Benatti Luca Director | Grant or award · Employee Stock Option (right to buy) | +27,000 | 27,000 | ||
| 2024-06-05 | Patni Rajiv Director | Grant or award · Employee Stock Option (right to buy) | +13,500 | 13,500 | ||
| 2024-06-04 | Hannah Brendan CHIEF BUSINESS OFFICER AND COO | Option exercise | +56,061 | $0.55 | $31K | 257,616 |
| 2024-06-04 | Hannah Brendan CHIEF BUSINESS OFFICER AND COO | Option exercise · Employee Stock Option (right to buy) | −56,061 | 47,439 | ||
| 2024-02-15 | Patni Rajiv Director | Grant or award · Employee Stock Option (right to buy) | +54,000 | 54,000 | ||
| 2024-02-01 | Ryan Charles S. PRESIDENT | Grant or award · Employee Stock Option (right to buy) | +145,000 | 145,000 | ||
| 2024-02-01 | Hannah Brendan CHIEF BUSINESS OFFICER AND COO | Grant or award · Employee Stock Option (right to buy) | +600,000 | 600,000 | ||
| 2024-02-01 | Thye Dirk CEO AND CHIEF MEDICAL OFFICER | Grant or award · Employee Stock Option (right to buy) | +1,500,000 | 1,500,000 | ||
| 2024-01-16 | Thye Dirk CHIEF EXECUTIVE OFFICER | Option exercise | +90,531 | $0.55 | $50K | 539,442 |
| 2024-01-16 | Thye Dirk CHIEF EXECUTIVE OFFICER | Option exercise | +149,999 | $0.94 | $141K | 689,441 |
| 2024-01-16 | Thye Dirk CHIEF EXECUTIVE OFFICER | Option exercise · Employee Stock Option (right to buy) | −90,531 | 115,860 | ||
| 2024-01-16 | Thye Dirk CHIEF EXECUTIVE OFFICER | Option exercise · Employee Stock Option (right to buy) | −149,999 | 450,001 | ||
| 2023-12-14 | Lamond David Director | Purchase | +22,627 | $1.04 | $24K | 2,347,545 |
| 2023-12-13 | Lamond David Director | Purchase | +22,627 | $1.00 | $23K | 2,324,918 |
| 2023-12-12 | Lamond David Director | Purchase | +300 | $1.00 | $300 | 2,279,964 |
Page 4 of 8 · 149 trades